Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs by Tannock, I F & Lee, C
There is a very large literature describing the appearance of
various markers of apoptosis following treatment of cells with
anti-cancer drugs. In the majority of these studies there is either an
explicit statement or an implicit assumption that chemotherapy has
led to cell death by initiating an apoptotic pathway. However, as
pointed out by Smets (1994) and others (Brown and Wouters,
1999), activation of the apoptotic pathway might occur either (A)
as a primary event induced by therapy, or (B) as a secondary event
following lethal damage to the cell (Fig. 1). This distinction is not
trivial, because if apoptosis occurs as a primary event following
chemotherapy (or after treatment with radiation or other agents),
then the effectiveness of treatment will depend on the cell’s ability
to activate the apoptotic pathway, and hence on the expression of
genes that initiate, regulate or mediate the pathway. The effective-
ness of treatment could, in principle, be modified through up-or
down-regulation of the apoptotic pathway, and mutations leading
to defective apoptosis would have the potential for causing drug
resistance. In contrast, if apoptosis were a secondary event which
occurred in cells that had sustained lethal damage (e.g. to DNA)
and merely controlled the rate of lysis of cells that had already lost
their reproductive potential, manipulation of the pathway would
have no influence on the long-term effects of treatment. 
Most studies that have investigated the appearance of apoptotic
changes following treatment of malignant cells with anti-cancer
drugs have used either an ‘apoptotic index’ as the endpoint of cell
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Figure 1 Pathways that might lead to apoptotic cells following cancer
treatment. (A) Apoptosis is induced by radiation or drugs and leads to cell
death. The process might then be modified to influence sensitivity to
treatment. (B) Radiation or drugs cause lethal damage to the cell, which in
turn induces apoptosis as a mechanism of cell lysis. Modification of apoptosis
will then influence the timing of cell lysis but not the proportion of surviving
cells 
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death (e.g. the proportion of cells that are positive in an assay for
apoptosis, such as TUNEL assay), or a simple measure of ‘cell
viability’ such as exclusion of trypan blue or another dye.
However, the measure of cell death that is most relevant for a
population of tumour cells is reproductive cell death as measured
by a colony-forming assay: a cell that cannot produce a colony of
progeny under optimal conditions is unlikely to be able to repro-
duce the tumour. There is a substantial, although older, literature
(e.g. Roper and Drewinko, 1976) that has shown very poor agree-
ment between the assessment of cell death by loss of clonogenic
capacity, and morphological markers or the inability to exclude
dyes. In general, cells that have sustained a lethal event may retain
their morphological appearance and exclude dyes for some period
after they have lost their reproductive potential. Moreover,
successful treatment with an anti-cancer drug implies reduction in
survival on a logarithmic scale (i.e. doses tolerated in vivo should
reduce survival to the range of 10–2 to 10–3 or lower) whereas prop-
erties such as apoptotic index, morphological change or loss of dye
exclusion are inherently limited to a linear scale. Changes in
‘viability’ assessed by these methods are difficult or impossible to
measure below a level of about 5–10%. 
A few studies have examined the relationship between apoptotic
markers and clonogenic cell survival following treatment of cells
with anti-cancer drugs or with radiation, and have come to
conflicting conclusions: changes in expression of genes that regu-
late apoptosis, such as bcl-2 or bax has led to changes in clonogenic
survival after treatment with radiation or drugs in some studies 
(Hu et al, 1995; Sakakura et al, 1996) but have had no effect on
clonogenic survival in others (Aldridge et al, 1995; Yin and
Schimke 1995; Lock and Strabinskiene, 1996; Kyprianou et al,
1997; Beale et al, 1998). It is possible that publication bias may
have limited the appearance of other studies that failed to show a
correlation. In the present study we have evaluated markers of
apoptosis following treatment with three types of cell with several
anti-cancer drugs that are in common use. The cells selected for this
study were (i) MGH-U1 human bladder cancer cells (also known as
T24) which are known to contain wild type p53 (Chang and Lai,
2000); (ii) CHO Chinese hamster ovary cells known to contain
mutant p53 (Hu et al, 1999); (iii) CTLL-2 murine T-cell leukaemia
cell line, which is known to express apoptotic markers following a
variety of stimuli, and which was used as a positive control to rule
out technical problems in assays of apoptosis. We have used doses
and exposure times that led to loss of reproductive integrity in a
substantial proportion of the cells (>90% or at least a 10-fold reduc-
tion in survival). In addition we have sought evidence for a cause
and effect relationship between apoptosis and loss of reproductive
integrity by transfecting and expressing the genes bcl-2 or bax in
human cells and studying their clonogenic survival following treat-
ment with doxorubicin and etoposide, two drugs which have been
widely reported to cause cell death by apoptotic mechanisms. Our
results suggest that apoptosis is not a major mechanism leading to
cell killing by anti-cancer drugs for MGH-U1 and CHO cells. 
MATERIALS AND METHODS 
Cell lines 
Human bladder cancer MGH-U1 cells were obtained originally from
Dr G Prout (Massachusetts General Hospital, Boston, MA, USA),
Chinese Hamster Ovary (CHO) cells were obtained originally from
Dr LH Thompson (Lawrence Livermore Laboratories, CA, USA).
These cell lines were maintained as monolayers in α - minimal essen-
tial medium (α -MEM) supplemented with 10% fetal calf serum
(FCS), and were re-established from frozen stock at about 6-month
intervals. The murine T-cell leukaemia cell line (CTLL-2) was
obtained from the American Tissue Culture Collection (TIB214);
this cell line was maintained in α -MEM +10% FCS supplemented
with 50 µ M interleukin 2 (IL2). Cell lines were checked routinely for
the presence of mycoplasma, using the Hoechst 33258 fluorescent
detection method, and were found to be negative. 
Anti-cancer drugs 
We evaluated the effects of the following anti-cancer drugs on
markers of apoptosis and on cell survival: cisplatin (Faulding,
Vaudreuil, Quebec), cytosine arabinoside (Upjohn, Don Mills, ON),
doxorubicin (Pharmacia, Mississauga, ON), etoposide (Novopharm,
Toronto, ON) and gemcitabine (Eli Lilly, Indianapolis, Indiana). The
drugs were prepared from our standard pharmacy formulations as
used for patients, and then further diluted in phosphate buffered
saline (PBS). 
Transfection of bcl-2 and bax genes 
MGH-U1 cells were stably transfected with neo/pcDNA3, full-
length human bcl-2/pcDNA3 or human bax/pcDNA3 by lipofect-
amine and selected in 1 mg/ml G418. For each cell type,
individual drug-resistant colonies were analysed by Western blot
analysis using either anti-human bcl-2 (Dako, Mississauga, ON,
Canada) or anti-human bax (Santa Cruz Biologicals, CA, USA)
antibodies. 
Detection of apoptosis 
Two methods were used to detect apoptosis in cells at various
times after drug treatment: (I) the presence of ‘DNA ladders’ in
DNA gel electrophoresis and (II) the Terminal deoxynucleotidyl
transferase-mediated dUTP Nick End-Labelling (TUNEL) assay.
Two positive controls were used for each of these assays to ensure
that failure to detect apoptotic markers was not due to technical
reasons; these were overgrown CHO cells in monolayer culture
(i.e. grown beyond the stage of confluence), and CTLL-2 cells
following withdrawal of IL2. Experiments are only reported here
if the results were repeatable, and if concurrent positive controls
showed unequivocal evidence of apoptosis. 
For DNA gel electrophoresis, DNA was isolated and analysed
as described previously (Brezden et al, 1994). Briefly, cells were
trypsinized, collected in tissue culture tubes and washed with PBS
before resuspension in 200 µ l of 5 M guanidine thiocyanate
containing 0.1 M 2-mercaptoethanol. DNA was precipitated by
addition of 150 µ l of 7.5 M ammonium acetate followed by 600 µ l
of 100% ethanol and incubated at –20˚C for at least 1 hour.
Samples were centrifuged at 14 000 rpm for 30 min at 4˚C. The
DNA pellet was washed twice with 500 µ l of 75% ethanol, air-
dried and redissolved in 10 mM Tris/1 mM EDTA at pH 8.0. The
DNA was fractionated by electrophoresis through a 2% agarose
gel prestained with ethidium bromide. 
The TUNEL assay 
The TUNEL assay was performed by using the APO-BRDU kit
(Phoenix Flow Systems, CA, USA). Briefly, cells were fixed in102 IF Tannock and C Lee
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1% paraformaldehyde in PBS for 15 min. Cells were then washed
and labelled with DNA labelling solution containing TdT reaction
buffer, TdT enzyme and Br-dUTP for 1 hour at 37˚C. At the end of
incubation, cells were rinsed and stained with fluorescein~PRB-1
antibody and propidium iodide/RNase A solution for 30 min in the
dark at room temperature. Br-dUTP is added to the 3′ -OH ends of
DNA fragments in apoptotic cells which can be recognized by
their fluorescence. The population of apoptotic and non-apoptotic
cells were distinguished by setting appropriate gates following
flow cytometry. 
Assessment of cell survival by clonogenic assay 
The survival of CHO cells and MGH-U1/neo cells following treat-
ment with various anti-cancer drugs was assessed by a colony-
forming assay. The survival of MGH-U1 cells transfected with bax
or bcl-2 genes was also compared with that of parental cells trans-
fected with the control vector (neo) following a 1 hour exposure to
varying doses of doxorubicin or etoposide. 
Exponentially growing cells were trypsinized and cells at a
concentration of 105 ml–1 were exposed to drugs. At the end of the
incubations, cells were washed 3 with PBS, trypsinized and
resuspended in α -MEM. The cells were counted, serially diluted
and plated in triplicate. Resulting colonies were stained with 
methylene blue and counted about 10 days later. Cell survival was
expressed as the ratio of the plating efficiency of treated cells to
that of untreated cells, and was plotted (using a logarithmic scale)
against drug concentration. All experiments were performed at
least twice. 
RESULTS 
Expression of bax and bcl-2
A Western blot showing expression of bax (p21) and bcl-2 (p26)
proteins in MGH-U1 cells is shown in Figure 2. The level of
expression of these proteins is increased substantially compared to
cells transfected with vector alone (designated MGH-U1/neo). 
Apoptosis following drug treatment 
Representative results of experiments using DNA electrophoresis
are shown in Figure 3; DNA ladders indicating the presence of
apoptosis were found reproducibly in gels for CTLL-2 cells
following withdrawal of IL2 from the growth medium, and for
CHO cells that were overgrown. As summarized in Tables 1–3,
DNA ladders were found at 24 h following treatment of CTLL-2
cells with cisplatin and gemcitabine, but not at 1 h to 24 h following
treatment with cytosine arabinoside, doxorubicin or etoposide.
DNA ladders were not seen after treatment of MGH-U1 or CHO
cells (including those transfected with bcl-2 or bax) with any of the
5 anti-cancer drugs at various concentrations and exposure times. 
Representative distributions of cells in the TUNEL assay are
shown in Figure 4, and results following treatment of the 3 cell
lines with anti-cancer drugs are summarized in Tables 1–3. The
only TUNEL assays which demonstrated a substantial number of
apoptotic cells were for overgrown CHO cells and for CTLL-2
cells after IL2 withdrawal. In addition to the conditions described
in Tables 1–3, markers of apoptosis were not observed when CHO
cells were treated with a variety of anti-cancer drugs and observed
for periods of time ranging up to 6 days (data not shown). 
Assessment of cell survival 
The surviving fractions of CHO and MGH-U1/neo cells following
treatment with the various anti-cancer drugs are shown in Tables 1
and 2. Depending on the drug concentration and duration of treat-
ment these drugs were able to cause substantial reduction in clono-
genic survival (with the exception of treatment of MGH-U1 cells
by cytosine arabinoside). 
The pooled results of 3 experiments to evaluate the survival of
MGH-U1 cells transfected with bcl-2, bax or the control vector
(neo) following treatment with doxorubicin or etoposide are
shown in Figure 5. There is no effect of bcl-2 or bax expression on
cell survival following treatment with etoposide; there is a small
effect of bcl-2 transfection to protect, and of bax transfection to
enhance cell killing after treatment with doxorubicin. 
DISCUSSION 
Understanding the role of apoptotic or other active mechanisms in
cell death following treatment of cells with anti-cancer agents is of
fundamental importance. If anti-cancer drugs or radiation cause
damage to cells that can lead to either cell death or to repair of
damage and viability, depending on the stimulation and activity of
apoptotic pathways, then these pathways might be manipulated to
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Figure 2 Western blots indicating expression of bax and bcl-2 protein
following transfection into MGH-U1 cells 
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Figure 3 DNA gel electrophoresis for CTLL-2 cells for the following
conditions. (1) 100 bp DNA marker; (2 and 3) doxorubicin 0.9 and 1.8 µ M
respectively; (4 and 5) etoposide 20 and 40 µ M respectively; (6 and 7)
cisplatin 10 and 20 µ M respectively; (8 and 9) gemcitabine 50 and 100 µ M
respectively; (10) control; (11) CHO overgrown cells and (12) withdrawal of
IL2 from CTLL-2 cells. For duration of exposure and timing of assay, see
Table 3. Ladders indicating presence of DNA breaks and apoptosis are
evident only in lanes 6, 7, 8, 9, 11 and 12Apoptosis in anti-cancer drugs 103
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Table 1 Summary of experiments to detect apoptotic markers and survival fraction (using a colony-forming assay) for MGH-U1/neo cells treated with a variety
of anti-cancer drugs. Treatment of MGH-U1/bax and MGH-U1/bcl-2 cells under the same conditions also did not lead to DNA ladders, and the proportion of
apoptotic cells in the TUNEL assay was consistently < 3.5% 
MGH-U1/neo 
Drug Dose Duration Interval to assay DNA ladders TUNELa Survival fractionb
Doxorubicin 0.9 µ M 1 h 24 h neg 0.4% 0.22 ± 0.06 
1.8 µ M 1 h 24 h  neg 0.2% 0.045 ± 0.02 
Etoposide 20 µ M 1 h 24 h neg 0.2% 0.124 ± 0.057 
40 µ M 1 h 24 h neg 0.4% 0.024 ± 0.015 
Cisplatin 10 µ M 24 h imm  neg 0.3% 3.0 ± 0.5 10–4 
20 µ M 24 h imm neg  0.3% 3.0 ± 0.3 10–4 
Ara C 50 µ M 24 h imm neg 5.6% 0.72 ± 0.14 
100 µ M 24 h imm neg  6.2% 0.69 ± 0.11 
Gemcitabine 50 µ M 24 h imm  neg 7.4% 0.011 ± 0.005 
100 µ M 24 h imm neg  7.4% 0.011 ± 0.001 
aPercent apoptotic cells by TUNEL assay; b± SEM; imm = immediate; neg = no ladders seen. 
Table 2 Summary of experiments to detect apoptotic markers and survival fraction (using a colony-forming assay) for CHO cells treated with a variety of anti-
cancer drugs. Markers of apoptosis were not observed when CHO cells were treated with a variety of anti-cancer drugs for extended period of time at intervals
from 0 to 6d (data not shown) 
CHO 
Drug Dose Duration Interval to assay DNA ladders TUNEL  Survival fraction 
Doxorubicin 0.18 µ M 18 h imm neg NA 0.12 ± 0.03 
0.45 µ M 18 h imm neg  NA 1.0 ± 0.1 10–3 
0.9 µ M 1 h 24 h  NA 0.5% 5.0 ± 0.2 10–4 
1.8 µ M 1 h 24 h  NA 3.6% NA 
Etoposide 20 µ M 1 h 24 h NA 0.7% 0.34 ± 0.05 
40 µ M 1 h 24 h neg 0.3% 0.46 ± 0.13 
Cisplatin 10 µ M 24 h imm  NA 0.2% 5.0 ± 0.6 10–4 
20 µ M 24 h imm neg  0.2% 0 
Ara C 50 µ M 24 h imm NA  0.2% 0.74 ± 0.04 
100 µ M 24 h imm NA  0% 0.08 ± 0.03 
Gemcitabine 50 µ M 24 h imm  neg 0.2% 3.0 ± 0.3 10–3 
100 µ M 24 h imm neg  0.2% 2.0 ± 0.7 10–3 
Overgrown cells imm pos 57% NA 
NA = Not available. 
Table 3 Summary of experiments to detect apoptotic markers for CTLL-2 cells treated with a variety of anti-cancer drugs 
CTLL-2 
Drug Dose Duration Interval to assay DNA Ladders TUNEL 
Doxorubicin 0.9 µ M 1 h 24 h neg 2.1% 
1.8 µ M 1 h 24 h  neg 1.1% 
Etoposide 20 µ M 1 h 24 h neg 12% 
40 µ M 1 h 24 h neg 18% 
Cisplatin 10 µ M 24 h imm  pos 1.1% 
20 µ M 24 h imm pos 0.8% 
Ara C 50 µ M 24 h imm neg 0.9% 
100 µ M 24 h imm neg  2% 
Gemcitabine 50 µ M 24 h imm  pos 0.6% 
100 µ M 24 h imm pos  6.9% 
IL2 withdrawal 24 h imm pos 38%  104 IF Tannock and C Lee
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influence sensitivity to these agents. For example, inhibition of the
bcl-2 protein in tumour cells, or up-regulation of the bax protein or
of caspases might be used to increase killing of tumour cells, and
would be of therapeutic value if these manipulations could be
undertaken selectively in tumour tissue. Conversely, up-regulation
of bcl-2 or of other genes that protect against apoptosis might be
important causes of resistance to drugs or radiation. However, as
illustrated conceptually in Figure 1, the observation of apoptotic
markers after treatment with radiation and drugs is not strong
evidence of their having a primary role in cell death. If the apop-
totic process is initiated in cells that have undergone lethal and
irreversible damage, markers of apoptosis may indicate only the
process of cell lysis in cells that have already lost reproductive
potential. 
Most of the published evidence relating to the role of apoptosis
following treatment with anti-cancer drugs or radiation is indirect.
Many authors have simply recorded the presence of various
markers of apoptosis and have assumed either explicitly or implic-
itly that there is a cause and effect relationship between their
expression and loss of cell viability. Other studies have correlated
the expression of pro-or anti-apoptotic genes in a variety of human
cancers with their overall responsiveness to therapy: some have
found a positive relationship (Kramer et al, 1996; Tai et al, 1998)
whereas others have not (Pereira et al, 1997; Veronese et al, 1998).
Even in studies which show a positive correlation, a cause and
effect relationship has not been established. 
In the present paper we have compared directly the loss of repro-
ductive potential following treatment with anti-cancer agents with
the appearance of apoptotic markers in CHO, MGH-U1 and CTLL-
2 cells. Apoptosis is known to depend on p53 status, with immediate
activation of apoptosis following DNA damage depending on the
presence of wild-type p53. The MGH-U1 (and CTLL-2) cells are
known to contain wild-type p53 whereas CHO cells are known to be
mutant for p53 (Hu et al, 1999; Chang and Lai, 2000). However, all
of these cells were quite sensitive to several anti-cancer drugs in
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Figure 5 Survival fraction (measured by a colony-forming assay) for 
MGH-U1/neo (  ), MGH-U1/bax (  ) and MGH-U1/bcl-2 (  ) cells following 
1 hour treatments with (A) doxorubicin and (B) etoposide. Symbols indicate
mean and standard error from 3 independent experimentsApoptosis in anti-cancer drugs 105
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common use, yet apoptotic markers were apparent in at most a small
fraction of the population even when clonogenic survival was in the
range of 10–4 to 10–1. Also we were able to transfect and express at
high levels the pro-apoptotic human gene bax and the anti-apoptotic
human gene bcl-2 in human MGH-U1 cells but found either no or
minor effects on their clonogenic survival after treatment with
etoposide and doxorubicin. These results are in accord with those of
several other studies (Aldridge et al, 1995; Yin and Schimke, 1995;
Lock and Strabinskiene, 1996; Kyprianou et al, 1997; Beale et al,
1998) although we were able to find two studies where changes in
expression of genes that control apoptosis was able to modify clono-
genic survival: for treatment of leukaemia cells with cytosine arabi-
noside (Hu et al, 1995) and for treatment of human breast cancer
MCF-7 cells with radiation (Sakakura et al, 1996). 
The role of apoptosis in mechanisms leading to loss of viability (in
the important sense of loss of reproductive potential) following anti-
cancer treatment is probably cell-line and drug-dependent. However,
several studies, including the one presented here, suggest little or no
role of apoptotic mechanisms in the killing of several types of cells
by anti-cancer drugs beyond the trivial one of promoting lysis of cells
that are already reproductively dead. The common assumption that
the observation of apoptosis after treatment with anti-cancer agents
implies its importance in determining therapeutic sensitivity or resist-
ance may not be justified. 
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